Lead optimization of aryl hydrocarbon receptor ligands for treatment of inflammatory skin disorders

• Published in: Biochemical pharmacology 2023-02, Vol.208, p.115400, Article 115400
• Main Authors: Rikken, Gijs, Smith, Kayla J., van den Brink, Noa J.M., Smits, Jos P.H., Gowda, Krishne, Alnemri, Angela, Kuzu, Gulsum E., Murray, Iain A., Lin, Jyh-Ming, Smits, Jos G.A., van Vlijmen-Willems, Ivonne M., Amin, Shantu G., Perdew, Gary H., van den Bogaard, Ellen H.
• Format: Article
• Language: English
• Subjects: Humans; Inflammation - metabolism; Keratinocytes - metabolism; Ligands; Receptors, Aryl Hydrocarbon - metabolism; Skin - metabolism; Skin Diseases - drug therapy
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2022.115400

[Display omitted] Therapeutic aryl hydrocarbon receptor (AHR) modulating agents gained attention in dermatology as non-steroidal anti-inflammatory drugs that improve skin barrier properties. By exploiting AHR’s known ligand promiscuity, we generated novel AHR modulating agents by lead optimization of a selective AHR modulator (SAhRM; SGA360). Twenty-two newly synthesized compounds were screened yielding two novel derivatives, SGA360f and SGA388, in which agonist activity led to enhanced keratinocyte terminal differentiation. SGA388 showed the highest agonist activity with potent normalization of keratinocyte hyperproliferation, restored expression of skin barrier proteins and dampening of chemokine expression by keratinocytes upon Th2-mediated inflammation in vitro. The topical application of SGA360f and SGA388 reduced acute skin inflammation in vivo by reducing cyclooxygenase levels, resulting in less neutrophilic dermal infiltrates. The minimal induction of cytochrome P450 enzyme activity, lack of cellular toxicity and mutagenicity classifies SGA360f and SGA388 as novel potential therapeutic AHR ligands and illustrates the potential of medicinal chemistry to fine-tune AHR signaling for the development of targeted therapies in dermatology and beyond.